Company intelligence / Profile preview

MorphoSys AG

Planegg/Munich area, Bayern/Bavaria, Germanymorphosys.com ↗

Ownership: Public · MOR
Employees: ~500
Development stage: Commercial

Overview

MorphoSys has developed multiple antibody-based therapeutics, with its first approved product being Tremfya® for plaque psoriasis, marketed by Janssen. Its own drug Monjuvi® (tafasitamab-cxix), co-developed with Incyte, received FDA accelerated approval in 2020 for certain lymphomas. Lead pipeline assets include Pelabresib and Tulmimetostat, both focused on oncology indications. The company was acquired by Novartis in 2024.

Therapeutic areas: OncologyImmunology
Modalities: Monoclonal antibodies (mAbs)Small molecules
Industry: Biotech

Drug pipeline

4 assets

tafasitamab

Commercial

Indications: Diffuse large B-cell lymphoma, Follicular lymphoma

3 more assets in the full pipeline.

Request access →

Partnerships

Janssen (Tremfya®, licensing)Incyte Corporation (Monjuvi®, global collaboration)Xencor, GSK, I-Mab Biopharma, Cherry Biolabs

Financials

Market cap: $2.9B
Total revenue: $27.5M
Enterprise value: $2.5B

Beyond the preview

Go deeper on MorphoSys AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MorphoSys AG.

Explore the full profile